INOVIO PHARMACEUTICALS, INC.

Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.

INO | NDAQ

Overview

Corporate Details

ISIN(s):: US45773H4092
LEI:
Country:: United States of America
Address:: 660 W. GERMANTOWN PIKE, 19462 PLYMOUTH MEETING
Website:: https://www.inovio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of DNA medicines. The company's proprietary platform designs DNA plasmids—small, circular DNA molecules that instruct the body's cells to produce specific proteins to target and fight disease. These DNA medicines are delivered directly into cells using INOVIO's proprietary investigational CELLECTRA® smart devices. This delivery method is designed for optimal effect without the use of chemical adjuvants, lipid nanoparticles, or viral vectors. INOVIO's development pipeline is focused on treatments and preventives for HPV-related diseases, cancer, and infectious diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all INOVIO PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for INOVIO PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for INOVIO PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Cellectis S.A. Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.	United States of America	CLLS
Cellid Co., Ltd. Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.	South Korea	299660
Cellromax Science Co., Ltd. Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.	South Korea	471820
CellSeed Inc. Develops cell sheet products, culture equipment, and offers contract manufacturing services.	Japan	7776
CellSource Co.,Ltd. Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.	Japan	4880
Celltrion, Inc. A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.	South Korea	068270
Celon Pharma S.A. Researches, develops, and markets innovative drugs for oncology and neurology.	Poland	CLN
CEL SCI CORP Develops immunotherapies for cancer, autoimmune, and infectious diseases.	United States of America	CVM
Celularity Inc Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.	United States of America	CELU
Centessa Pharmaceuticals plc Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.	United States of America	CNTA